FDA’s new expert panels are rife with financial conflicts and fringe views

WASHINGTON (AP) — When the Food and Drug Administration needs outside guidance, it normally turns to a trusted source: a large roster of expert advisers who are carefully vetted for their independence, credentials and judgment. But increasingly, the agency isn’t calling them. Instead, FDA Commissi

Redirecting to full article...